相关实验视频

Updated: May 24, 2025

Exploring m6A and m5C Epitranscriptomes upon Viral Infection: an Example with HIV

Exploring m6A and m5C Epitranscriptomes upon Viral Infection: an Example with HIV

Published on: March 5, 2022

m6A肝细胞癌的表体转录组修饰:对瘤微环境和免疫疗法的影响

Fen Liu¹, Qingbin Liu², Xianying Li²

¹Institute of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.

Frontiers in immunology

|March 4, 2025

概括

N6-甲基氨酸 (m6A) RNA修饰影响肝细胞癌 (HCC) 中的瘤免疫微环境 (TIME). 向m6A通路提供了一种新的策略,以克服免疫抵抗并提高HCC患者的免疫疗法疗效.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.

背景情况:

肝细胞癌 (HCC) 是癌症死亡的主要原因,往往是晚诊断的.
免疫疗法,特别是免疫检查点抑制剂 (ICI),已经显示出希望,但面临着诸如瘤异质性和免疫逃避等挑战.
了解瘤免疫微环境 (TIME) 对于改善HCC治疗结果至关重要.

研究的目的:

审查N6-甲基氨酸 (m6A) RNA修饰在塑造HCC时间中的作用.
探索m6A如何影响免疫细胞,细胞因子动态和PD-L1表达.
讨论针对m6A的治疗潜力,以提高HCC的免疫治疗疗效.

主要方法:

文献综述侧重于m6A修饰在HCC.
在时间内分析m6A对免疫细胞功能和细胞因子概况的影响.
检查m6A调节剂作为生物标志物和治疗点.

主要成果:

m6A修饰在调节RNA稳定性和HCC中免疫相关因素的翻译方面发挥着关键作用.
m6A影响PD-L1表达,有助于免疫逃逸和ICI耐药性.
与m6A相关的调节剂被确定为免疫治疗反应的潜在生物标志物.

结论:

m6A修饰是HCC免疫微环境的关键决定因素.
准m6A通路是一个有前途的策略,可以克服HCC的免疫疗法耐药性.
对m6A机制的进一步研究可以为先进的HCC带来新的治疗方法.

关键词:

肝细胞癌是肝细胞癌.免疫检查点抑制剂免疫检查点抑制剂免疫疗法耐药性免疫疗法耐药性 m6A 修改的修改瘤免疫的微环境

更多相关视频

A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties

A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties

Published on: August 7, 2020

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

Published on: September 25, 2013

相关概念视频

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...